| 5.18 Real-Time Quote |  -0.20 / -3.72%Today’s Change | 3.65 Today|||52-Week Range 13.45 | -0.19% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $160.4M |
Company Description
Omeros Corp. is a clinical stage biopharmaceutical company engages in discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The company's products are derived from its proprietary PharmacoSurgery platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. It also has a deep and diverse pipeline of preclinical programs as well as a platform capable of unlocking new drug targets. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.
Employees
Shareholders
| Mutual fund holders | 9.37% |
| Other institutional | 18.73% |
| Individual stakeholders | 10.74% |
Top Executives
| Gregory A. Demopulos, MD | Chairman, President, CEO, CFO & Treasurer |
| George A. Gaitanaris, PhD, MD | Chief Scientific Officer & Vice President |
| Clark E. Tedford, PhD | Vice President-Research |
| J. Steven Whitaker, MD | Chief Medical Officer & VP-Clinical Development |
| Kenneth M. Ferguson, PhD | Chief Development Officer & Vice President |
.
